Browsing Tag
DURAVYU
2 posts
EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout
EyePoint completes Phase 3 DME enrollment as DURAVYU targets six-month dosing, with wet AMD data due in August and DME results in late 2027.
EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the…